Frank Hull, MD
Pulmonary Disease · Plantation, FLNPI 1407832744
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $58,720 of the $89,886 with a category attached, or 65.3%. 54 manufacturers reported payments, led by AstraZeneca at 49.9% of the total. Reporting peaked in 2023 at $35,920 and has fallen 94.7% since, to $1,915 in 2025. Among pulmonary disease clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 643 payments — averaging $139.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$45K
- GSK$11K
- Astrazeneca UK Limited$11K
- Insmed, Inc.$7K
- Intuitive Surgical$4K
- AbbVie$2K
- plus $11K from 48 others
Across 209 payments — averaging $5189.17 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$383K
- AstraZeneca$342K
- Sanofi US Services Inc.$311K
- Insmed, Inc.$21K
- Roche Products Limited$18K
- Actelion Pharmaceuticals US, Inc.$7K
- plus $4K from 1 others
What the payments were for
- Consulting fees$58,72065%
- Speaking & faculty fees$11,15012%
- Travel & lodging$1,8892%
- Food & beverage$13,75315%
- Education$4,3755%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FASENRA$53,301
- Arikayce$5,991
- NUCALA$4,754
- TRELEGY ELLIPTA$4,309
- ION$3,000
- AVYCAZ$1,827
- Da Vinci Surgical System$1,007
- Adempas$400
- Photofrin$300
- UPTRAVI$288
- OPSUMIT$288
- Inspire Upper Airway Stimulation System$133
- DUPIXENT$130
- Yupelri$125
- AIRSUPRA$125
- BREZTRI AEROSPHERE$123
- Ohtuvayre$117
- BREZTRI$114
How this compares
$89,886 in reported general payments places this provider in the 90th percentile of 953 pulmonary disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 256 | $212,995 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 52 | $44,114 |
| Spiriva RespimatTiotropium Bromide | 47 | $29,168 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 48 | $23,191 |
| Breo ElliptaFluticasone/Vilanterol | 33 | $19,334 |
| EliquisApixaban | 15 | $12,512 |
| SymbicortBudesonide/Formoterol Fumarate | 46 | $12,134 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 14 | $10,917 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 11 | $7,079 |
| Advair HfaFluticasone Propion/Salmeterol | 20 | $5,999 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 300 | $5,623 |
| Varenicline Tartrate | 14 | $5,222 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 12 | $5,205 |
| Arnuity ElliptaFluticasone Furoate | 16 | $3,572 |
| BreynaBudesonide/Formoterol Fumarate | 12 | $3,418 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta | $10,811 | $259,092353 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $44,883 | $61,453110 claims |
| Boehringer IngelheimSpiriva Respimat, Combivent Respimat, Stiolto Respimat | $601 | $47,16472 claims |
| PfizerEliquis | $251 | $12,51215 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 953 pulmonary disease providers in Florida.
Other pulmonary disease in Plantation
- Franck RahaghiWeston$1.2M
- Michael OttEglin Afb$909K
- Ali JiwaniOrlando$859K
- Anas HadehWeston$800K
- Jennifer FultonJacksonville$665K
- Ricardo Restrepo-JaramilloTampa$555K
- Mark RumbakTampa$528K
- Jose Soto SotoJacksonville$504K
- Javier Perez FernandezMiami$496K
- Domenick ReinaTampa$469K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.